Booth Mark D 4
4 · Orexigen Therapeutics, Inc. · Filed Jan 18, 2013
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2013-01-15$1.66/sh+22,315$37,043→ 22,315 total - Sale
Common Stock
2013-01-15$6.67/sh−22,215$148,174→ 100 total - Sale
Common Stock
2013-01-15$6.67/sh−100$668→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2013-01-15−22,315→ 706,376 totalExercise: $1.66Exp: 2021-07-24→ Common Stock (22,315 underlying)
Footnotes (4)
- [F1]The exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2012.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2012.
- [F3]1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each one-month period of the reporting persons service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting persons continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- [F4]Not applicable.